Study Summary
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens. The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.
Want to learn more about this trial?
Request More InfoInterventions
CAR-CD19 T cellGENETIC
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-BCMA T cellGENETIC
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-GPC3 T cellGENETIC
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-CLD18 T cellGENETIC
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
FludarabineDRUG
Fludarabine is used for lymphodepletion.
CyclophosphamideDRUG
Cyclophosphamide is used for lymphodepletion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| First Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang | China |